Matthew Henn
Chief Tech/Sci/R&D Officer at SERES THERAPEUTICS, INC.
Net worth: 49 099 $ as of 30/03/2024
Profile
Matthew R.
Henn is currently the Chief Scientific Officer & Executive VP at Seres Therapeutics, Inc. He previously worked as a Director at Viral Genomics, Inc. and as a Director-Viral Genomics at The Broad Institute, Inc. Dr. Henn holds a doctorate degree from the University of California, Berkeley and an undergraduate degree from the University of New Hampshire.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SERES THERAPEUTICS INC
0.04% | 15/02/2024 | 63,436 ( 0.04% ) | 49 099 $ | 30/03/2024 |
Matthew Henn active positions
| Companies | Position | Start |
|---|---|---|
| SERES THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 06/02/2019 |
Former positions of Matthew Henn
| Companies | Position | End |
|---|---|---|
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 31/05/2012 |
| Viral Genomics, Inc. | Director/Board Member | - |
Training of Matthew Henn
| University of California, Berkeley | Doctorate Degree |
| University of New Hampshire | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SERES THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
| Viral Genomics, Inc. | |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Matthew Henn
